国家药监局修订孟鲁司特制剂说明书：患者用药不良反应中个别涉及抑郁和自杀倾向

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations to enhance public medication safety, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's decision is based on the evaluation of adverse drug reactions, aiming to ensure safer medication use among the public [1] - The revised warning will include reports of neuropsychiatric adverse reactions across all age groups, including severe reactions such as depression and suicidal tendencies [1] Group 2: Patient Guidance - The new instructions recommend that if neuropsychiatric symptoms occur during treatment with Montelukast, the medication should be discontinued and medical attention sought [1] - Patients and caregivers are advised to be vigilant for neuropsychiatric adverse reactions and to inform healthcare providers if related symptoms arise during the medication period [1]